Rocket Pharmaceuticals adjusted the clinical trial design to include use of approved drug to avert an excessive immune response to its Danon disease gene therapy. The patient who died was one of two who received this drug under the revised protocol.
The post Death in Rocket Pharma Gene Therapy Study Puts Spotlight on Trial Change Intended to Improve Safety appeared first on MedCity News.
